Literature DB >> 3402524

Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.

J van Harten1, P van Brummelen, J H Wilson, M T Lodewijks, D D Breimer.   

Abstract

The pharmacokinetics and effects on blood pressure and heart rate of nisoldipine were studied in 8 patients with cirrhosis and in 8 age-matched healthy controls. On separate occasions each subject received nisoldipine by i.v. infusion (0.37 mg in 40 min) and as a tablet (5 mg for patients and 20 mg for control subjects). After i.v. nisoldipine, the elimination half-life was 9.7 h in control subjects and 16.6 h in the cirrhotics. The volume of distribution was 4.1 l/kg and 6.4 l/kg and the total systemic clearance was 847 ml/min and 494 ml/min, respectively. On oral nisoldipine, systemic availability was fourfold higher in patients with cirrhosis: 14.7% versus 3.7%. After i.v. administration of nisoldipine there was a brief decrease in systolic and diastolic blood pressure in both groups, whereas the heart rate increased. After 4 h a second effect peak appeared in the control subjects. After oral nisoldipine similar effect-time profiles were found, but effects lasted longer than after i.v. administration. Comparison of the maximal total plasma concentration of nisoldipine and the maximal effect in the two groups revealed that sensitivity to nisoldipine was not different in patients with cirrhosis. A reduction in the dose of nisoldipine is recommended when cirrhotics require oral nisoldipine in therapeutic practice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402524     DOI: 10.1007/bf00542441

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Gas chromatographic determination of nisoldipine and one of its metabolites in plasma.

Authors:  J Van Harten; M T Lodewijks; J W Guyt-Scholten; P Van Brummelen; D D Breimer
Journal:  J Chromatogr       Date:  1987-12-25

3.  Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.

Authors:  J van Harten; P van Brummelen; M T Lodewijks; M Danhof; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1988-03       Impact factor: 6.875

4.  Salutary hemodynamic and sustained clinical beneficial effects of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure.

Authors:  A Kimchi; A G Ellrodt; Y Charuzi; W Shell; G H Murata
Journal:  Am Heart J       Date:  1985-08       Impact factor: 4.749

5.  Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis.

Authors:  A Koshy; A Hadengue; S S Lee; M I Jiron; D Lebrec
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

6.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

7.  Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls.

Authors:  F M Gengo; S C Fagan; G Krol; H Bernhard
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

8.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

9.  Pharmacokinetics and metabolism of nifedipine.

Authors:  K D Raemsch; J Sommer
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

10.  A comparison of the haemodynamic effects of nifedipine, nisoldipine and nitrendipine in man.

Authors:  N M Debbas; S H Jackson; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  14 in total

Review 1.  Systems dynamics in clinical pharmacokinetics. An introduction.

Authors:  J M van Rossum; J E de Bie
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

2.  Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.

Authors:  D J McConn; Y S Lin; T L Mathisen; D K Blough; Y Xu; T Hashizume; S L Taylor; K E Thummel; M C Shuhart
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 5.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 6.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 7.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 8.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 9.  Clinical pharmacokinetics of mibefradil.

Authors:  H A Welker; H Wiltshire; R Bullingham
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 10.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.